Tonix Pharmaceuticals 的股票飙升，因为 FDA 跳过了新的纤维肌痛药物审查咨询委员会。 Tonix Pharmaceuticals' stock soars as FDA skips Advisory Committee for new fibromyalgia drug review.

在FDA宣布不需要咨询委员会会议来审查TNX-102 SL后,Tonix制药公司的份额暴涨。 TNX-102 SL是治疗纤维分裂症的一种可能的新疗法。 Shares of Tonix Pharmaceuticals surged after the FDA announced it wouldn't require an Advisory Committee meeting for the review of TNX-102 SL, a potential new treatment for fibromyalgia. 如果得到批准,TNX-102 SL将是15年多以来第一种新的纤维分裂性损伤新药物。 If approved, TNX-102 SL would be the first new drug for fibromyalgia in over 15 years. 美国食品和药物管理局此前已授予快速通道指定,以加快审查过程. The FDA has previously granted Fast Track designation to expedite the review process. 托尼克斯计划在2025年底前推出该药物,等待批准。 Tonix plans to launch the drug by the end of 2025, pending approval.